Cloverleaf Bio $33M Seed Financing
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 10, 2026
The financing signals continued venture appetite for early-stage RNA therapeutics and validates industry interest from three major pharma venture arms at the preclinical stage, a modest positive for sentiment toward the biotech venture funding environment. Direct public-market impact is limited given Cloverleaf is private, though the participation of AbbVie, Eli Lilly and Company, and Boehringer Ingelheim highlights strategic interest in tRNA-based oncology platforms.
Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and included strategic participation from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, alongside Draper Gain International, Mission BioCapital, and American Cancer Society BrightEdge. The simultaneous participation of three major pharmaceutical venture arms at the preclinical stage reflects strong industry interest in the company's engineered transfer RNA (tRNA) platform, which is built around selective and durable inhibition of multiple RNA-modifying enzymes that cancer cells become abnormally dependent on as they proliferate. Proceeds will advance two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing, and an antibody-tRNA conjugate targeting colorectal cancer through preclinical development. The lead compound CLB-001 reportedly demonstrated greater potency and selectivity for cancer cells over healthy cells in preclinical studies, retained activity in cancer cell lines resistant to frontline chemotherapy and current-generation ADC payloads, and outperformed frontline standards of care in hepatocellular carcinoma and lung adenocarcinoma models at substantially lower doses. Animal tolerability studies reportedly showed no increases in markers of liver damage and no signs of systemic toxicity. Cloverleaf's early research was supported in part by funding from the United States — National Cancer Institute under the NIH SBIR/STTR program. The company was founded by Austin Draycott, Cole Lewis, and Wendy Gilbert.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard